Tackling neurology with cannabinoids
Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline approval. We arrive at an initial valuation of $38.4m or $10.97 per ADS.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Tackling neurology with cannabinoids29 Jun 2017